Lewis Joel's Form 4 filing
Galectin Therapeutics Inc (GALT) · filed Apr 25, 2024
- Accession no.
- 0001133416-24-000040
- Filed
- Apr 25, 2024
- Trade date
- Apr 24, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $3.39K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lewis JoelCIK 0001725595 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 24, 2024 | Common Stock | PPurchaseAcquired | +1,000 | $3.39F1 | +$3,390 | 2,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents average price in multiple transactions with low of $3.30 per share and high of $3.41 per share
Referenced by the price of 1 transaction in Table I.